血液透析滤过与高通量血液透析的死亡风险比较:跨国目标试验模拟
该研究利用欧洲8国透析登记数据,模拟目标试验比较血液透析滤过(HDF)与高通量血液透析的死亡风险。纳入2014至2019年成人每周三次中心透析患者,HDF与较低全因死亡风险相关(HR 0.72,95%CI 0.67-0.77),2年绝对风险降低1.7个百分点。
要点
- HDF与高通量血液透析相比全因死亡风险更低(HR 0.72)。
- 2年加权累积死亡率HDF组20.6%,透析组22.3%。
- 心血管疾病患者中HDF的相对获益更明显。
核心结论
- 持续高通量后稀释HDF与高通量血液透析相比与较低的全因死亡风险相关。
研究设计与样本
- 利用欧洲临床数据库(8国透析登记)模拟目标试验,纳入2014-2019年成人每周三次中心透析患者,随访从透析开始后91天起。
主要发现
- 在19,539例 eligible 患者中,逆概率加权创建19,758例加权伪人群(HDF 8641例;高通量血液透析11,117例)。
- 中位随访16个月(IQR 6-32),发生4282例死亡。
- HDF与较低全因死亡风险相关(HR 0.72;95%CI 0.67-0.77)。
- 2年加权累积死亡率HDF组20.6%,高通量血液透析组22.3%,绝对风险降低1.7个百分点。
- 预设亚组中仅已有心血管疾病患者观察到更强的相对获益(交互P < 0.001)。
关键数值与推荐
- 持续治疗策略定义为至少90%的 sessions 接受指定模式。
- 主要结局为全因死亡,肾移植作为竞争事件。
临床怎么用
- 在技术可行且临床适当时,支持更广泛使用HDF。
局限性
- 较高对流容积与更好生存相关,但可能反映患者稳定性和中心经验而非因果剂量反应关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KEY POINTS: Randomized trials suggested that hemodiafiltration improved survival over high-flux hemodialysis, but real-world evidence is limited. Target trial emulation showed that hemodiafiltration was associated with lower mortality than high-flux hemodialysis. The findings supported broader use of hemodiafiltration when technically feasible and clinically appropriate. BACKGROUND: Randomized trials suggest that high-volume postdilution hemodiafiltration (HDF) may improve survival compared with high-flux hemodialysis, but evidence from routine clinical practice and from regions underrepresented in trials remains limited. METHODS: We emulated a target trial comparing HDF with high-flux hemodialysis using data from European Clinical Database, a multinational registry of dialysis patients treated in 8 European countries. Adults receiving thrice-weekly in-center dialysis between 2014 and 2019 were eligible. Follow-up began 91 days after dialysis initiation. Sustained treatment strategies were defined as receipt of the assigned modality for at least 90% of sessions. Inverse probability weighting was used to emulate randomized treatment assignment. The primary outcome was all-cause mortality, with kidney transplantation treated as a competing event. RESULTS: Among 19,539 eligible patients at day 91, inverse probability weighting created a weighted pseudopopulation of 19,758 patients (8641 HDF; 11,117 hemodialysis). During a median follow-up of 16 months (interquartile range, 6-32), 4282 deaths occurred. HDF was associated with a lower risk of all-cause mortality compared with high-flux hemodialysis (hazard ratio, 0.72; 95% confidence interval, 0.67 to 0.77). At 2 years, the weighted cumulative incidence of death was 20.6% in the HDF group and 22.3% in the hemodialysis group, corresponding to an absolute risk reduction of 1.7% points. The results were consistent across sensitivity analyses, including analyses accounting for country, competing risks, informative censoring, protocol adherence, and an intention-to-treat-like exposure definition. The association was broadly similar across prespecified subgroups, with only a stronger relative benefit observed among patients with preexisting cardiovascular disease (interaction P < 0.001). Higher delivered convective volumes were associated with better survival; however, these findings should be interpreted cautiously because higher convective volumes may reflect patient stability and center expertise rather than a causal dose-response relationship. CONCLUSIONS: In this large multinational target trial emulation, sustained high-volume postdilution HDF was associated with lower mortality than high-flux hemodialysis.
引用
- Strippoli GFM, Tripepi G, Canaud B, et al. Hemodiafiltration versus High-Flux Hemodialysis and Risk of Mortality: A Multinational Target Trial Emulation. J Am Soc Nephrol. 2026. PMID: 42593876. doi:10.1681/ASN.0000001225
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。